Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446) Meeting Abstract


Authors: Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; Ostrovnaya, I.; Ghossein, R. A.; Chen, H. X.; Humm, J.; Carducci, M. A.; Larson, S. M.; Pfister, D. G.; Fagin, J. A.; Ho, A. L.
Abstract Title: Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680301791
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.6089
Notes: Meeting Abstract: 6089 -- This meeting was also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James A Fagin
    181 Fagin
  2. Ronald A Ghossein
    485 Ghossein
  3. Robert M Tuttle
    483 Tuttle
  4. Eric J Sherman
    342 Sherman
  5. Ravinder K Grewal
    82 Grewal
  6. Sofia S Haque
    149 Haque
  7. David G Pfister
    389 Pfister
  8. Shrujal S Baxi
    107 Baxi
  9. John Laurence Humm
    434 Humm
  10. Alan Loh Ho
    240 Ho
  11. Mona M Sabra
    43 Sabra
  12. Steven M Larson
    959 Larson
  13. Stephanie Anne Fish
    25 Fish
  14. Keith S Pentlow
    70 Pentlow
  15. Laura   Boucai
    48 Boucai
  16. Bharat Burman
    13 Burman
Related MSK Work